CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2012	Dec. 31, 2011
Current assets
Cash	$ 576,823	$ 952,252
Prepaid drug product for testing	21,000	153,000
Other current assets	56,330	48,439
Total current assets	654,153	1,153,691
Other assets
Technology licenses - related party	2,893,877	2,868,877
Less Accumulated Amortization	(839,572)	(791,463)
Intangible Assets, Net (Excluding Goodwill), Total	2,054,305	2,077,414
TOTAL ASSETS	2,708,458	3,231,105
Current liabilities
Accounts payable	58,447	121,540
Accounts payable - related party		67,971
Accrued expense	70,910	46,082
Accrued expense - related party	52,700	41,000
Accrued license payments - related party	64,538	39,538
Total current liabilities	246,595	316,131
Long term debt
TOTAL LIABILITIES	246,595	316,131
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding
Common Stock, $.001 par value, 200,000,000 shares authorized 58,493,920 and 58,325,169 shares issued and outstanding as of 3/31/12 and 12/31/11, respectively	58,494	58,325
Additional paid in capital	12,474,343	12,405,395
Accumulated deficit during development stage	(10,070,974)	(9,548,746)
Total shareholders' equity	2,461,863	2,914,974
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 2,708,458	$ 3,231,105